Danaher delivered a solid second quarter of 2026 with better-than-expected revenue, earnings and cash flow and accelerating core growth: sales rose 5.5% to $6.3 billion, core revenue grew 3% (4.5% excluding respiratory testing, a 150-basis-point acceleration from Q1), GAAP net earnings were $870 million or $1.23 per diluted share (up 60%), and adjusted EPS grew 8% to $1.94. Life Sciences delivered its strongest quarter in several years at 5.5% core growth, led by ~10% growth at Pall on semiconductor/microelectronics demand and Abcam's best quarter since acquisition, while Diagnostics grew 5% excluding respiratory and Biotechnology grew 2.5%. The quarter's main blemish was bioprocessing: a few large chromatography-resin shipments (~$50-60 million in Q2, more than $100 million for the full year) were pushed out to 2027 at commercial customers' request, cutting the full-year bioprocessing outlook from high-single- to mid-single-digit even as underlying consumables and equipment orders grew mid-teens; adjusted operating margin also slipped 20 basis points to 27.1% on lower respiratory revenue. Free cash flow was strong at $1.3 billion (124% first-half conversion), and Danaher advanced its capital-deployment flywheel by closing Masimo early (immediately accretive, high-single-digit growth), announcing the pending ~$250 million StatLab acquisition for Leica Biosystems, and repurchasing 5 million shares for ~$900 million. The early Masimo close and strong execution let management again raise full-year adjusted EPS guidance to $8.45-$8.60 (nearly 10% growth at the midpoint), while anchoring full-year core growth to the low end of 3%-4%, with respiratory headwinds of ~150 bps in Q2 and ~250 bps in Q3 fading to neutral in Q4 to drive a mid-single-digit exit rate; management emphasized a multi-year bioprocessing CapEx/reshoring cycle, improving biotech funding, stabilizing academic markets, and early AI-driven automation demand.
Good morning, everyone. Thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer, and Matt Gugino, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release quarterly report on Form 10-Q, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call, and a note containing details of historical and anticipated future financial performance are all available on the investors section of our website, danaher.com, under the heading Quarterly Earnings. The audio portion of this call will be archived on the investors section of our website later today under the heading Events and Presentations and will remain archived until our next quarterly call. A dial-in replay of this call will also be available until August fourth, 2026.
During the presentation, we will describe certain of the more significant financial factors that impacted year-over-year performance. Our Form 10-Q and the supplemental materials I referenced describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the second quarter of 2026. All references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future.
These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings. Actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made. We do not assume any obligation to update any forward-looking statements except as required by law. With that, I'd like to turn the call over to Rainer.
Thank you, Rachel, good morning, everyone. We appreciate you joining us on the call today. We delivered a solid second quarter with better-than-expected revenue, earnings, and cash flow. We were particularly pleased to see an acceleration in core growth versus the first quarter, driven by good commercial execution, recent innovation, and recovery in our end market. Our life sciences businesses delivered their strongest quarter in several years. Diagnostics continued to perform well. While customer project timing impacted bioprocessing revenue, underlying order trends remained robust. Improved growth across our portfolio, paired with benefits from our recent productivity initiatives, helped drive high single-digit earnings growth. This strong execution and the earlier-than-expected close of Masimo enables us to again raise our full year adjusted EPS guidance.
The quarter illustrates the benefit of our balanced end market and geographic diversification while reinforcing our outlook for accelerating revenue and earnings growth in the second half and beyond. Across our end markets, we saw encouraging signs of stabilization and improvement. Demand from large pharma and biopharma customers remained healthy, while improved biotech funding supported improved funnel and order activity. Academic and government markets have largely stabilized, while clinical and applied remained consistent sources of strength across the portfolio. As we look to the second half of 2026 and beyond, we're encouraged by the momentum across our businesses and the long-term value creation opportunities ahead for us. We're well-positioned in attractive end markets with strong secular growth drivers. Our capital deployment flywheel is active, supported by significant balance sheet optionality. The Danaher Business System and our team are powerful differentiators, helping us drive both growth and productivity.
With that, let's take a closer look at our second quarter 2026 results. Sales were $6.3 billion in the second quarter. Core revenue was up 3% year-over-year. Core growth, excluding respiratory testing revenue, which highlights improvements in the underlying business trends that I mentioned a moment ago, was up 4.5%, 150 basis point acceleration from the first quarter. We were encouraged to see growth accelerate with improving trends across our end markets and recent innovations further driving growth across our businesses. Let me briefly highlight a few examples of how these innovations are strengthening our competitive position and helping customers bring life-changing therapies and diagnostics to patients faster and more efficiently. In biotechnology, Cytiva launched the Biacore 8S SPR system, a high-throughput screening and characterization platform that helps researchers evaluate how potential drug candidates interact with their targets.
By combining rapid screening with high-quality molecular characterization and AI-powered data analysis in a single automated platform, Biacore 8S helps customers identify the most promising drug candidates faster. In life sciences, SCIEX reinforced its leadership position in mass spectrometry with the introduction of the novus V55 at June's American Society for Mass Spectrometry Meeting. This AI-enabled triple quadrupole system delivers enhanced sensitivity, high-throughput, and helps reduce operating costs for pharmaceutical, food, clinical, and environmental testing labs. In diagnostics, Beckman Coulter introduced the Access BD-pTau217 Research Use Only assay and received the CE mark approval for the Access p-tau217 assay, two blood-based Alzheimer's biomarker tests for use on the DxI 9000. Those assays further strengthen Beckman's positioning as a leader in the important and growing area of neurodegenerative diagnostics.
Now, these are just a few of many examples across Danaher and how we're positioning our businesses for continued growth and delivering on our commitment to help customers solve some of the most important challenges impacting patients around the world. Geographically, core revenues in developed markets declined slightly as both North America and Western Europe were impacted by shipment timing in biotechnology and lower respiratory revenue year-over-year. Core revenues in high-growth markets increased more than 10%, with healthy growth across our major regions, including mid-single-digit growth in China. In China, biotechnology delivered another quarter of solid growth as local companies continued to partner with Cytiva on the development of novel molecules and the manufacturing of commercial therapies.
Life sciences market conditions continued to stabilize while diagnostics improved sequentially as we began to move beyond the most significant year-over-year impacts of volume-based procurement and reimbursement changes that began in late 2024. Our gross profit margin for the second quarter was 57.6%. Our adjusted operating profit margin of 27.1% was down 20 basis points as lower respiratory revenue year-over-year more than offset the favorable impacts of higher non-respiratory volume and disciplined cost management. Adjusted diluted net earnings per common share of $1.94 were up approximately 8% year-over-year. We generated $1.3 billion of free cash flow in the quarter and $2.4 billion in the first half of the year, resulting in a year-to-date free cash flow to net income conversion ratio of 124%, further underwriting the differentiated quality of our earnings.
We also made significant progress on our capital deployment priorities during the quarter and into July. On the M&A front, we closed our acquisition of Masimo in early June, ahead of our initial expectations. We expect Masimo to be immediately accretive, both strategically and to adjusted EPS. The business delivered high single-digit revenue growth in the first half of the year and is off to a great start as part of Danaher, including an FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection solution. In fact, the team has already completed their first operating review, where they further validated opportunities to drive productivity and efficiency improvement, capture customer account synergies, and strengthen the innovation process using the Danaher Business System Launch Excellence tool. Additionally, Leica Biosystems announced the pending acquisition of StatLab, a leading manufacturer of consumables across the anatomical pathology workflow.
StatLab has built a strong reputation with customers for its quality, innovation, and customer intimacy. We believe the acquisition will strengthen Leica Biosystems' value proposition by bringing together consumables, instruments, automation, and digital pathology into a more complete workflow solution. It also supports our broader integrated delivery network strategy and our goal of helping clinicians diagnose cancer faster and more precisely. StatLab generated approximately $250 million in revenue for the full year of 2025 and has an attractive business model with more than 85% recurring revenue. We expect the business to grow high single digits over the long term and to be accretive to adjusted EPS in our first full year of ownership. While the transaction remains subject to customary closing conditions, including regulatory approvals, we expect to close by the end of 2026.
Lastly, we deployed approximately $900 million of capital to repurchase 5 million shares of Danaher common stock. We believe these repurchases will provide an attractive return given the trajectory of our long-term organic growth, earnings, and cash flow outlook. Now let's take a closer look at our results across the portfolio and give you some color on what we saw in our end markets. Core revenue in our biotechnology segment increased 2.5%. Core revenue in discovery and medical increased mid-single digits, with solid growth in pharma and biopharma, and a more stable academic and research funding environment. Core revenue in bioprocessing grew low single digits in the second quarter, with low single-digit growth in both consumables and equipment. We were encouraged to see equipment growth in the second quarter following several quarters of improving order trends, supported by customer investments in manufacturing capacity.
Consumables growth came in below our expectations, as a few large shipments for programs at our commercial customers moved out of the quarter. To give you some additional color, this was a shift in shipment timing at a few large commercial drug manufacturers for molecules that were specced into. While revenue was impacted by customer timing, underlying demand remained very healthy, with mid-teens order growth in both consumables and equipment. The trends we're seeing in the business, together with healthy underlying demand, reinforce our confidence in the high single-digit long-term outlook for Cytiva's bioprocessing franchise. Cytiva is well-positioned to support capacity expansions as we expect onshoring activity to accelerate and commercial production to remain robust, particularly in monoclonal antibodies.
At the same time, new molecules continue to progress through development pipelines and into commercialization, creating what we believe is a durable long-term growth opportunity given Cytiva's leading and expanding specced-in position on molecules in pre-clinical and early-stage clinical development phases. Turning to our Life Sciences segment, core revenue increased 5.5%. Core revenue in Pall's applied filtration business increased approximately 10%, led by strength in its microelectronics product line. This business provides mission-critical filtration solutions across the semiconductor manufacturing workflow and has been a consistent growth driver for Pall over the last several years. Core revenue in our Life Sciences instrument businesses increased mid-single digits in the quarter. Across our end markets, investment from large pharma and biopharma customers continued to strengthen, while biotech demand benefited from a more favorable funding environment. Academic demand improved modestly as the quarter progressed but remained below normal levels.
By operating company, we saw solid growth at Beckman Life Sciences, Leica Microsystems, and SCIEX. Beckman Life Sciences saw notable growth in automation, where the team is well-positioned to benefit as customers invest in the lab infrastructure needed to support autonomous labs and AI-enabled drug discovery. Core revenue in our Life Sciences consumables businesses collectively grew low single digits. IDT was up in the quarter, led by demand for MRD testing solutions, and Abcam's growth continued to accelerate, delivering its best quarter since acquisition as academic markets have started to improve and commercial initiatives, particularly around biopharma and diagnostic end markets, gained further traction. As end market conditions continue to improve, we expect commercial and go-to-market execution, including autonomous lab-catalyzed demand, to further support growth acceleration across Abcam, IDT, and Aldevron. Moving to our Diagnostics segment, core revenue increased 2%. Core growth, excluding respiratory testing revenue, was up 5%.
Thanks, Rainer. That concludes our formal comments. We're now ready for questions.